IL17A and psoriasis vulgaris: Brodalumab is a human IgG2 monoclonal antibody with a high affinity for IL-17 receptor A (IL-17RA), which is used, in part, by IL-25 in addition to IL-17A, IL-17C, IL-17F, and the IL-17A/F heterodimer to transduce intracellular signals [85, 86] Although currently approved to treat moderate-to-severe plaque psoriasis that is refractory to other therapies [85], Busse et al. [86] executed a phase 2a, randomized, double-blind, placebo-controlled, clinical trial to assess the effectiveness of brodalumab as a treatment for moderate-to-severe asthma.